{"text": ["Agree", "To", "Purchase", "AbbVie", "At", "$55,", "Earn", "3.2%", "Using", "Options"], "created_at": "2018-06-19 17:06:11"}
{"text": ["Agree", "To", "Purchase", "AbbVie", "At", "$55,", "Earn", "3.2%", "Using", "Options"], "created_at": "2018-06-19 17:06:11"}
{"text": ["8,000", "AbbVie", "Employees", "Volunteer", "Across", "Five", "Continents", "During", "Fifth-Annual", "\"Week", "of", "Possibilities\""], "created_at": "2018-06-19 13:21:00"}
{"text": ["Wired", "News", "\u2013", "AbbVie", "Presents", "New", "Undetectable", "Minimal", "Residual", "Disease", "Data", "from", "Phase-3", "MURANO", "Trial", "of", "Venetoclax", "with", "Rituximab", "at", "23rd", "European", "Hematology", "Association", "Annual", "Congress"], "created_at": "2018-06-19 11:20:00"}
{"text": ["3", "Great", "Reasons", "to", "Buy", "Gilead", "Sciences"], "created_at": "2018-06-19 10:32:00"}
{"text": ["Bristol-Myers", "Posts", "Data", "on", "Empliciti,", "China", "Approves", "Opdivo"], "created_at": "2018-06-19 00:07:43"}
{"text": ["Bristol-Myers", "Posts", "Data", "on", "Empliciti,", "China", "Approves", "Opdivo"], "created_at": "2018-06-19 00:07:43"}
